Treating diabetes with autologous cell therapy: an interview with Orgenesis

In this exclusive interview, learn more about the development of an autologous cell therapy for diabetes.

In this exclusive interview, Vered Caplan, President, Chief Executive Officer and Director, and Professor Sarah Ferber, Chief Scientific Officer, Orgenesis, discuss the development of an autologous cell therapy for the treatment of insulin-resistant diabetes. 

Orgenesis is a biopharmaceutical company with experience in cell therapy development and manufacturing. In this video, filmed exclusively at  the Alliance for Regenerative Medicine’s EU Investor Day, learn more about the challenges of developing patient-derived cell therapies.

Want more from the Alliance for Regenerative Medicine’s EU Investor Day?

• Read “The ‘point of the spear’ for regenerative medicine commercialization: an interview with Janet Lambert”
• Read “RegMedNet at the 5th Annual European Advanced Therapies Investor Day”
• Watch “Next generation CAR-Treg therapies: an interview with Stéphane Boissel”